NeOnc Technologies Holdings Inc
NASDAQ:NTHI
ROE
Return on Equity
ROE, or Return on Equity, is a key financial ratio that measures a company's profitability. Specifically, it measures how many dollars of profit are generated for each dollar of shareholder's equity. A higher ROE indicates better financial performance and effective use of capital, making it a valuable metric for investors assessing a company's earning potential.
ROE Across Competitors
Country | Company | Market Cap | ROE | ||
---|---|---|---|---|---|
US |
N
|
NeOnc Technologies Holdings Inc
NASDAQ:NTHI
|
94.2m USD |
423%
|
|
US |
![]() |
Eli Lilly and Co
NYSE:LLY
|
765B USD |
78%
|
|
UK |
![]() |
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
-4%
|
|
US |
![]() |
Johnson & Johnson
NYSE:JNJ
|
407.2B USD |
31%
|
|
DK |
![]() |
Novo Nordisk A/S
CSE:NOVO B
|
2T DKK |
88%
|
|
CH |
![]() |
Roche Holding AG
SIX:ROG
|
213.2B CHF |
27%
|
|
CH |
![]() |
Novartis AG
SIX:NOVN
|
181B CHF |
33%
|
|
UK |
![]() |
AstraZeneca PLC
LSE:AZN
|
165.5B GBP |
20%
|
|
US |
![]() |
Merck & Co Inc
NYSE:MRK
|
211.2B USD |
39%
|
|
IE |
E
|
Endo International PLC
LSE:0Y5F
|
183.8B USD |
70%
|
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
143.9B USD |
9%
|
NeOnc Technologies Holdings Inc
Glance View
NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Calabasas, California. The company went IPO on 2025-03-26. The firm is focused on establishing treatments for intracranial malignancies, such as aggressive cancers located in the brain. The company is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company is developing novel drug delivery methods to be used in combination with novel drug candidates. The firm has two lead products in development: NEO100 and NEO212. NEO100 is a purified form of perillyl acid (POH) which is administered to brain cancer patients via intranasal delivery. NEO212 is a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol. NEO212 is undergoing development towards intranasal application specifically for patients with uncontrolled brain metastases derived from peripheral tumors (lung, breast, skin, and others).
See Also
ROE, or Return on Equity, is a key financial ratio that measures a company's profitability. Specifically, it measures how many dollars of profit are generated for each dollar of shareholder's equity. A higher ROE indicates better financial performance and effective use of capital, making it a valuable metric for investors assessing a company's earning potential.
Based on NeOnc Technologies Holdings Inc's most recent financial statements, the company has ROE of 422.7%.